Invivoscribe files sPMA with the FDA for use of the LeukoStrat...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SAN DIEGO, Oct. 24, 2022 /PRNewswire-AsiaNet/ -- Invivoscribe is pleased to announce that they have filed a supplemental Pre-Market Approval (sPMA) submission with the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) for the use of the LeukoStrat(R) CDx F...
Authors: LATEST ASIANET NEWS RELEASES